after semaglutide weight gain maintenance discontinuation of GLP-1 therapies Weight-loss: Are injections the answer

Advantages: Continuous appetite suppression Prevents weight regain during transition Preferred by patients with history of rapid rebound eating Disadvantages: Higher nausea and vomiting risk (estimated 35% vs 22% in first 2 weeks) Overlapping GLP-1 activation may transiently worsen gastroparesis symptoms Difficult to distinguish semaglutide vs tirzepatide side effects during overlap window Clinical data supporting overlap: a 2024 case series (Garvey et al., Journal of Clinical Endocrinology & Metabolism) described 89 patients who used 3-day overlap

NAFLD and NASH currently have no approved treatments though they impact 25% and 5% of U.S

Biomarker performance was evaluated using receiver operating characteristic (ROC) curve analysis based on exploratory multivariate models, calculating area under the curve (AUC), sensitivity, and specificity

(2020) 146(5):e2020029074

In this instance, the concentrations of doxorubicin required to induce a deleterious GSH response fall firmly outside of the therapeutic ranges of circulating doxorubicin reported 40

Ecotoxicity of some of them has been confirmed